A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma

BACKGROUND: Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesolin, Daniel, Alaref, Amer, Ibrahim, Mohammed F. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351660/
https://www.ncbi.nlm.nih.gov/pubmed/34713631
http://dx.doi.org/10.1002/cnr2.1567
_version_ 1784762482004328448
author Tesolin, Daniel
Alaref, Amer
Ibrahim, Mohammed F. K.
author_facet Tesolin, Daniel
Alaref, Amer
Ibrahim, Mohammed F. K.
author_sort Tesolin, Daniel
collection PubMed
description BACKGROUND: Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor use, although, few reports exist for pazopanib. CASE: Here we report a 69‐year‐old patient with minimal cardiovascular risk factors who developed a rupture of a splenic arterial aneurysm after more than 5 years of effective treatment with pazopanib for metastatic renal cell carcinoma. CONCLUSION: This case report outlines the necessity to monitor patients while on pazopanib, even when there are minimal risk factors and long periods of tolerance.
format Online
Article
Text
id pubmed-9351660
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93516602022-08-09 A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma Tesolin, Daniel Alaref, Amer Ibrahim, Mohammed F. K. Cancer Rep (Hoboken) Case Reports BACKGROUND: Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor use, although, few reports exist for pazopanib. CASE: Here we report a 69‐year‐old patient with minimal cardiovascular risk factors who developed a rupture of a splenic arterial aneurysm after more than 5 years of effective treatment with pazopanib for metastatic renal cell carcinoma. CONCLUSION: This case report outlines the necessity to monitor patients while on pazopanib, even when there are minimal risk factors and long periods of tolerance. John Wiley and Sons Inc. 2021-10-28 /pmc/articles/PMC9351660/ /pubmed/34713631 http://dx.doi.org/10.1002/cnr2.1567 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Tesolin, Daniel
Alaref, Amer
Ibrahim, Mohammed F. K.
A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title_full A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title_fullStr A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title_full_unstemmed A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title_short A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
title_sort case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351660/
https://www.ncbi.nlm.nih.gov/pubmed/34713631
http://dx.doi.org/10.1002/cnr2.1567
work_keys_str_mv AT tesolindaniel acaseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma
AT alarefamer acaseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma
AT ibrahimmohammedfk acaseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma
AT tesolindaniel caseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma
AT alarefamer caseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma
AT ibrahimmohammedfk caseofsplenicarteryaneurysmandruptureinapatientonavascularendothelialgrowthfactorinhibitorforrenalcellcarcinoma

Ejemplares similares